Capital International Ltd. CA Grows Holdings in Icon Plc $ICLR

Capital International Ltd. CA grew its stake in Icon Plc (NASDAQ:ICLR) by 569.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 29,246 shares of the medical research company’s stock after acquiring an additional 24,875 shares during the period. Capital International Ltd. CA’s holdings in Icon were worth $5,329,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. WINTON GROUP Ltd acquired a new position in Icon during the 2nd quarter worth approximately $254,000. Daiwa Securities Group Inc. grew its holdings in Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after acquiring an additional 4,546 shares in the last quarter. Frontier Capital Management Co. LLC grew its holdings in Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after acquiring an additional 35,253 shares in the last quarter. Peapack Gladstone Financial Corp acquired a new position in Icon during the 2nd quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after acquiring an additional 289 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on ICLR shares. DA Davidson set a $164.00 price target on shares of Icon in a report on Monday, June 1st. Piper Sandler cut shares of Icon to a “neutral” rating in a report on Thursday, May 28th. BMO Capital Markets upped their price objective on shares of Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research note on Friday, May 29th. Bank of America restated an “outperform” rating on shares of Icon in a research note on Monday, June 1st. Finally, Citigroup upped their price objective on shares of Icon from $120.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, May 29th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $156.44.

Icon Stock Down 2.2%

Shares of NASDAQ:ICLR opened at $149.45 on Friday. The stock has a market cap of $12.07 billion, a P/E ratio of 24.26, a P/E/G ratio of 10.13 and a beta of 1.26. The firm has a fifty day moving average price of $117.51 and a 200 day moving average price of $140.85. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.10 and a quick ratio of 1.10. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share for the quarter. The firm had revenue of $2.11 billion during the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Sell-side analysts predict that Icon Plc will post 9.74 EPS for the current year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.